SCHEMBL6495218

SCHEMBL6495218

CCOC(=O)CCCOc1ccc2nc(OCC)n(Cc3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
P2RY12 Q9H244 1/20 0.46
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MTNR1A P48039 6/20 0.43
MTNR1B P49286 6/20 0.43
PPARG P37231 1/20 0.43
PLA2G2A P14555 3/20 0.43
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CYSLTR2 Q9NS75 2/20 0.40
CYSLTR1 Q9Y271 2/20 0.40
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500625 0.91 FFAR1 (0.45) PDE3BPDE3AP2RY12LMNASMN1; SMN2
SCHEMBL6495068 0.91 PPARG (0.52) PDE3BPDE3AP2RY12LMNASMN1; SMN2
SCHEMBL6490102 0.87 LMNA (0.43) LMNASMN1; SMN2PPARGPLA2G2AMEN1
SCHEMBL6498632 0.86 PDE3B (0.48) PDE3BPDE3AP2RY12LMNAPPARG
SCHEMBL6503545 0.83 MCL1 (0.43) PDE3BPDE3AP2RY12PLA2G2AKMT2A
SCHEMBL6497461 0.83 PPARG (0.49) PDE3BPDE3AP2RY12LMNAPPARG
SCHEMBL6500673 0.81 PPARG (0.49) PDE3BPDE3AP2RY12LMNAPPARG
SCHEMBL6489678 0.81 MCL1 (0.41) PDE3BPDE3AP2RY12PLA2G2ACYSLTR2
SCHEMBL6501536 0.81 PPARG (0.52) PDE3BPDE3AP2RY12LMNASMN1; SMN2
SCHEMBL6487701 0.80 PPARG (0.49) PDE3BPDE3AP2RY12PPARGPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PDE3B 411/4885PDE3A 733/4885P2RY12 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.